Table 5.

Current phase 2/3 clinical trials of niraparib with other agents in advanced/metastatic epithelial ovarian cancer

Title	Mechanism	Current status	Phase	Target participants
Efficacy and Safety of Niraparib Combined with Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer (NCT04217798)	Topoisomerase inhibitor	Recruiting	2	35 participants
A Phase 3 Comparison of Platinum-based Therapy with TSR-042 and Niraparib versus SOC Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) (NCT03602859)	Anti-PD-1 inhibitor	Active, not recruiting	3	1045 participants
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer (ANNIE) (NCT04376073)	Anti-VEGFR, FGFR, PDGFR and ckit	Recruiting	2	40 participants
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response to Front-Line Platinum-Based Chemotherapy (NCT03326193)	Anti-VEGF	Active, non-recruiting	2	105 participants
Safety and Efficacy of AsiDNATM, a DNA repair inhibitor, administered IV in addition to niraparib in patients with relapsed platinum sensitive ovarian cancer already treated with niraparib (REVOCAN)	DNA repair inhibitor	Recruiting	1/2	26 participants
Platinum-based Chemotherapy with Atezolizumab and Niraparib in Patients with Recurrent Ovarian Cancer (ANITA)	Platinum-based chemotherapy and anti-PD-L1	Recruiting	3	414 participants
Efficacy and Safety of Niraparib Combined with Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (AVANIRA3)	Anti-VEGF	Recruiting	2	32 participants